Trials / Unknown
UnknownNCT02327715
Emtricitabine for Prevention of Vertical Transmission of HBV in Chinese Pregnant HBsAg Positive Patients
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Asian-Pacific Alliance of Liver Disease, Beijing · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates generic emtricitabine(FTC) efficacy and safety in Chinese naive pregnant HBsAg positive patients in prevention of HBV vertical transmission. Single group patients were enrolled to receive emtricitabine till 24 weeks after delivery.
Detailed description
Single group patients were enrolled to receive emtricitabine till 24 weeks after delivery, which include HBeAg positive patients. Patients and their newborns were followed till 48 weeks after delivery to evaluate the efficacy of prevention of vertical transmission.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Emtricitabine | emtricitabine were given to each patients from week 28 pregnancy to 24 weeks after delivery |
Timeline
- Start date
- 2015-01-01
- Primary completion
- 2015-07-01
- Completion
- 2016-07-01
- First posted
- 2014-12-30
- Last updated
- 2014-12-30
Source: ClinicalTrials.gov record NCT02327715. Inclusion in this directory is not an endorsement.